Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Silence Therapeutics plcNASDAQ: SLN

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$208.65K, compared with $727.63K a year earlier. Trailing-twelve-month accounts receivables was -$8.33M.

Context

  • Accounts receivables amounted to 906.1% of revenue in FY2025, up 904.4 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$208.65K or moves back toward the trailing-twelve-month quarterly average of -$2.08M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$208.65K-231.1% QoQ
Last fiscal yearDec 2025
$5.07M+801.2% YoY
LTMMar 2026
-$8.33M— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-128.7%——
1 year+801.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

Mixed currencies · from the cash flow

Latest · FY2025
5.07M USD
Year-over-year change
—

Accounts Receivables vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Accounts receivables amounts to 904.4% of revenue for SLN, versus a peer median of 0.7%.
SLN Competitors
Accounts Receivables for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$264.55M USD+194.3%—12.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$63.73M USD-14.2%-10.4%6.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M USD+6.6%—29.4%
SLNSilence Therapeutics plcLTM Mar 2026$8.33M USD——904.4%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$3.29M USD-94.2%—0.7%
WVEWave Life Sciences Ltd.LTM Mar 2026$177.78K USD+291.8%—0.2%
BNTCBenitec Biopharma Inc.LTM Mar 2026$8.07K USD-96.4%+481.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR——0.0%
RNAAtrium Therapeutics, Inc.FY2025$0 USD——0.0%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —-3.8%+235.7%0.7%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Net Income(61.89M)(50.33M)(50.31M)(28.92M)(88.61M)
Depreciation & Amortization576.29K596K498K473.86K555K
Deferred Income Tax5.95M688K0675.23K11K
Stock-Based Compensation11.65M12.69M13.05M10.41M8.07M
Change in Working Capital52.43M(19.4M)(11.66M)(26.39M)10.16M
Accounts Receivables37.09M(10.54M)314K(722.38K)5.07M
Inventory00000
Accounts Payables00000
Other Working Capital15.33M(8.85M)(11.98M)(25.67M)5.09M
Other Non-Cash Items468.32K(1.28M)9.07M(10.3M)7.54M
Operating Cash Flow9.19M(57.04M)(39.35M)(54.05M)(62.27M)
Capital Expenditures(1.8M)(545K)(45K)(168.61K)(55K)
Acquisitions (Net)00000
Purchases of Investments0(19.95M)(20.67M)(111.21M)(166.41M)
Sales of Investments13.5M036.18M0118.48M
Other Investing Activities(17.55K)(372K)958K93.82M0
Investing Cash Flow11.71M(20.5M)16.43M(17.55M)(47.99M)
Debt Repayment(284.77K)0(174K)00
Common Stock Issued41.73M52.58M25.33M113.54M15K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow41.45M52.58M25.16M113.54M15K
Effect of Forex Changes(141.71K)(8.12M)(3.02M)47.95K195K
Net Change in Cash62.2M(33.08M)(785K)41.98M(110.05M)
Free Cash Flow7.39M(57.59M)(39.4M)(54.22M)(62.33M)

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.